– CANADA, Edmonton – TRIO – Translational Research in Oncology, a global academic clinical research organization, today announced the appointment of Prof. Seock-Ah Im to its Board of Directors, effective March 15, 2021.
Based in South Korea, Prof. Seock-Ah Im brings significant experience in key areas including translational research and clinical trial development.
“On behalf of the Board of Directors, it is a pleasure to welcome Prof. Seock-Ah Im to the Board,” said Executive Director, Dr. Dennis Slamon. “Her collective experience, in and out of the laboratory, will complement our current Board of Directors’ skills and experiences. We look forward to working with Prof. Seock-Ah Im and leveraging her unique expertise.”
The appointment of Prof. Seock-Ah Im to TRIO’s Board builds upon a successful working history with the Korean Cancer Study Group.
Prof. Seock-Ah Im joins current board members:
- Dr. Peter Fasching,
- Dr. John Glaspy,
- Dr. Hari Kumar,
- Dr. Miguel Martin,
- Dr. Dennis Slamon
- Fran Visco.
About Prof. Seock-Ah Im
Dr. Seock-Ah Im currently holds the position of Director of Cancer Research Institute at Seoul National University. Her clinical work is focused on the development of tailored therapy through translational research and clinical trials to maximize clinical utility. In addition, she serves as Chair to both the International Cooperation Committee of the Korean Cancer Study Group and the Scientific Committee of the Korean Society of Medical Oncology.
About TRIO
TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting. With international offices in Edmonton (Canada), Paris (France), Montevideo (Uruguay), TRIO’s global reach is expansive. Our goal as an academic clinical research organization is to find the shortest path to saving lives.
For more information: https://www.trioncology.org/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.